Skip to content
value.today
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

TARA
$235 Mmarket cap on Aug 1, 2026+879.2% since Jan 2024
Compare
World rank
#15,679
Revenue
—
For year ending December-2025
Net income
$-57 M
SEC filing
Employees
51
As of December 31, 2025
SEC filing

Protara Therapeutics, Inc. in brief

Protara Therapeutics, Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $235 M on 1 August 2026, which makes it the 15,679th largest listed company in the world and the 3,057th largest in the USA on this site. It employs about 51 people and Jesse Shefferman is its chief executive. Its shares trade under the symbol TARA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Protara Therapeutics, Inc.

We are a New York City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in order to create new development opportunities. We prioritize creativity, integrity and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

Our portfolio includes two development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell therapy is currently approved in Japan and Taiwan for lymphatic malformations, or LMs, and multiple oncologic indications. We have secured worldwide rights to the asset excluding Japan and Taiwan and are exploring its use in oncology and rare disease indications. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical). We are currently developing TARA-002 in non-muscle invasive bladder cancer, or NMIBC, and LMs. We are also pursuing IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

From the company's annual report filed with the US SEC: read the report

Protara Therapeutics, Inc. timeline

4 events, 2006–2020
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. 🔔
    Initial public offering as Proteon Therapeutics Inc
    Final prospectus filed with the SEC on 22 October 2014; shares registered for exchange trading on 16 October 2014.
  5. 2019
  6. ✎
    Renamed ArTara Therapeutics, Inc.
    Formerly Proteon Therapeutics Inc.
  7. 2020
  8. ✎
    Renamed Protara Therapeutics, Inc.
    Formerly ArTara Therapeutics, Inc..

Events of Protara Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$82 M$165 M$247 M$329 M2023202420252026

World rank over time

▲ up 9,799 places since 2022
2022-01-07: #24746#24,74620222022-12-25: #27441#27,44120222023-07-30: #27856#27,85620232024-01-05: #28263#28,26320242026-03-08: #8315#8,31520262026-08-01: #14947#14,9472026

Rank in USA: #4,689 (Jan 2022) · #5,066 (Dec 2022) · #5,026 (Jul 2023) · #4,310 (Jan 2024) · #1,521 (Mar 2026) · #3,020 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.2×
Free cash flow yield
-24.0%
Net margin
—
Operating margin
—
Return on equity
-29.2%
Liabilities / assets
6.2%
R&D / revenue
218.0%
Profit per employee
$-1.1 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-21M—FY18Fiscal year ending Dec 2019: revenue —, net income $-8M—FY19Fiscal year ending Dec 2020: revenue —, net income $-34M—FY20Fiscal year ending Dec 2021: revenue —, net income $-47M—FY21Fiscal year ending Dec 2022: revenue —, net income $-66M—FY22Fiscal year ending Dec 2023: revenue —, net income $-40M—FY23Fiscal year ending Dec 2024: revenue —, net income $-45M—FY24Fiscal year ending Dec 2025: revenue —, net income $-57M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-65M$-57M—
Dec 2024——$-49M$-45M—
Dec 2023——$-44M$-40M—
Dec 2022——$-67M$-66M—
Dec 2021——$-47M$-47M—
Dec 2020——$-34M$-34M—
Dec 2019——$-8M$-8M—
Dec 2018——$-21M$-21M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-56M$0M$-56M$-1.34—
Dec 2024$-36M$0M$-36M$-2.17—
Dec 2023$-38M$0M$-38M$-3.57—
Dec 2022$-26M$0M$-27M$-5.86—
Dec 2021$-35M$1M$-35M$-4.21—
Dec 2020$-23M$1M$-24M$-4.70—
Dec 2019$-5M$0M$-5M$-3.04—
Dec 2018$-23M$0M$-23M$-45.80—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-13M—Dec ’24Three months to Mar 2025: revenue —, net income $-12M—Mar ’25Three months to Jun 2025: revenue —, net income $-15M—Jun ’25Three months to Sep 2025: revenue —, net income $-13M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-17M—Dec ’25Three months to Mar 2026: revenue —, net income $-18M—Mar ’26Three months to Jun 2026: revenue —, net income $-22M—Jun ’26Three months to Sep 2026: revenue —, net income $-22M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-22M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Protara Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-65 M
Net income
$-57 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$209 M
Total liabilities
$13 M
Total equity
$196 M

As of December-2025

Top 100 institutional investors in Protara Therapeutics, Inc.#

As of Sep 30, 2026
119 institutions held 46.5 M shares (about 75.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 39.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Protara Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.3,706,130+42,631 (+1.16%)6.02%$11 MNov 13, 2026
2Millennium Management LLC3,097,095-4,071 (-0.13%)5.03%$9 MNov 16, 2026
3Velan Capital Investment Management LP2,844,6520 (0.00%)4.62%$9 MNov 16, 2026
4Rosalind Advisors, Inc.2,400,000New3.90%$7 MNov 16, 2026
5Blackstone Inc.2,366,514+101,000 (+4.46%)3.84%$7 MNov 16, 2026
6Vanguard Capital Management LLC2,300,1330 (0.00%)3.74%$7 MNov 13, 2026
7Citadel Advisors LLC2,087,107+854,742 (+69.36%)3.39%$6 MNov 16, 2026
8Sio Capital Management, LLC1,991,339+69,467 (+3.61%)3.23%$6 MNov 16, 2026
9Baker Bros. Advisors LP1,843,795+872,181 (+89.77%)2.99%$6 MNov 16, 2026
10Acorn Capital Advisors, LLC1,752,1150 (0.00%)2.85%$5 MNov 16, 2026
11Marshall Wace, LLP1,543,284+842,263 (+120.15%)2.51%$5 MNov 13, 2026
125AM Venture Management, LLC1,369,7820 (0.00%)2.22%$4 MNov 16, 2026
13Geode Capital Management, LLC1,333,520+7,274 (+0.55%)2.17%$4 MNov 6, 2026
14Integral Health Asset Management, LLC1,250,000-250,000 (-16.67%)2.03%$4 MNov 16, 2026
15Qube Research & Technologies Ltd1,168,444+122,928 (+11.76%)1.90%$4 MNov 13, 2026
16Ameriprise Financial Inc1,119,841+1,063,574 (+1890.23%)1.82%$3 MNov 16, 2026
17State Street Corp1,048,080-20,215 (-1.89%)1.70%$3 MNov 12, 2026
18Palo Alto Investors LP1,035,964New1.68%$3 MNov 16, 2026
19Balyasny Asset Management L.P.1,003,180-23,511 (-2.29%)1.63%$3 MNov 16, 2026
20Walleye Capital LLC933,246+427,814 (+84.64%)1.52%$3 MNov 13, 2026
21Bank Of America Corp /de/919,340+37,161 (+4.21%)1.49%$3 MNov 16, 2026
22ADAR1 Capital Management, LLC850,512-90,000 (-9.57%)1.38%$3 MNov 16, 2026
23Dimensional Fund Advisors LP684,093+863 (+0.13%)1.11%$2 MNov 4, 2026
24Northern Trust Corp536,426-15,880 (-2.88%)0.87%$2 MNov 16, 2026
25Renaissance Technologies LLC531,830+280,330 (+111.46%)0.86%$2 MNov 12, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Protara Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Catalio Capital Management, LP512,287-7,861 (-1.51%)0.83%$2 MNov 16, 2026
27UBS Group AG373,239-83,534 (-18.29%)0.61%$1 MNov 10, 2026
28Vanguard Portfolio Management LLC363,536-128,121 (-26.06%)0.59%$1 MNov 13, 2026
29Vanguard Fiduciary Trust Co362,283+27,600 (+8.25%)0.59%$1 MNov 13, 2026
30Verdad Advisers, LP352,002+39,753 (+12.73%)0.57%$1 MNov 16, 2026
31Jane Street Group, LLC291,491New0.47%$1 MNov 12, 2026
32HRT Financial LP290,961New0.47%$1 MNov 13, 2026
33Two Sigma Investments, LP241,997+172,345 (+247.44%)0.39%$1 MNov 16, 2026
34Oppenheimer & Co Inc217,631-20,731 (-8.70%)0.35%$1 MOct 26, 2026
35Morgan Stanley211,030-297,404 (-58.49%)0.34%$1 MNov 13, 2026
36Point72 Asset Management, L.P.205,272-343,660 (-62.61%)0.33%$1 MNov 16, 2026
37Woodline Partners LP179,164New0.29%$1 MNov 16, 2026
38XTX Topco Ltd175,722+111,774 (+174.79%)0.29%$1 MNov 16, 2026
39Jump Financial, LLC173,600-29,500 (-14.52%)0.28%$1 MNov 13, 2026
40Goldman Sachs Group Inc159,713-386,514 (-70.76%)0.26%$0 MNov 16, 2026
41Charles Schwab Investment Management Inc157,252-719 (-0.46%)0.26%$0 MNov 16, 2026
42CIBC World Market Inc.150,995-15,500 (-9.31%)0.25%$0 MNov 10, 2026
43Bank of New York Mellon Corp142,939+5,250 (+3.81%)0.23%$0 MNov 5, 2026
44Fisher Asset Management, LLC129,612+30,046 (+30.18%)0.21%$0 MNov 6, 2026
45J. Goldman & Co LP108,000-27,000 (-20.00%)0.18%$0 MNov 16, 2026
46Cary Street Partners Financial LLC100,000New0.16%$0 MNov 12, 2026
47American Century Companies Inc98,145-342 (-0.35%)0.16%$0 MNov 12, 2026
48FMR LLC84,656+16,456 (+24.13%)0.14%$0 MNov 10, 2026
49Alps Advisors Inc77,735+20,694 (+36.28%)0.13%$0 MNov 3, 2026
50Nuveen, LLC72,633+23 (+0.03%)0.12%$0 MNov 10, 2026
51Bridgeway Capital Management, LLC69,830-15,500 (-18.16%)0.11%$0 MNov 16, 2026
52Two Sigma Securities, LLC69,693New0.11%$0 MNov 16, 2026
53Squarepoint Ops LLC68,685+50,561 (+278.97%)0.11%$0 MNov 9, 2026
54D. E. Shaw & Co., Inc.66,005+54,892 (+493.94%)0.11%$0 MNov 16, 2026
55Rhumbline Advisers65,337+2,092 (+3.31%)0.11%$0 MNov 10, 2026
56Empowered Funds, LLC62,500New0.10%$0 MNov 13, 2026
57Los Angeles Capital Management LLC62,225New0.10%$0 MNov 12, 2026
58Truist Financial Corp60,0000 (0.00%)0.10%$0 MOct 30, 2026
59Nano Cap New Millennium Growth Fund L P57,500+7,500 (+15.00%)0.09%$0 MNov 13, 2026
60Indivisible Partners51,124New0.08%$0 MOct 26, 2026
61Deutsche Bank AG\50,423-7,290 (-12.63%)0.08%$0 MNov 6, 2026
62Quadrature Capital Ltd48,420+9,101 (+23.15%)0.08%$0 MNov 13, 2026
63Price T Rowe Associates Inc /MD/47,822+9,339 (+24.27%)0.08%$0 MNov 16, 2026
64Odyssean, LLC44,205New0.07%$0 MNov 16, 2026
65Axq Capital, LP41,904New0.07%$0 MNov 12, 2026
66EntryPoint Capital, LLC40,906+21,620 (+112.10%)0.07%$0 MNov 13, 2026
67AQR Capital Management LLC37,310-171,659 (-82.15%)0.06%$0 MNov 16, 2026
68WINTON GROUP Ltd37,200+4,400 (+13.41%)0.06%$0 MNov 12, 2026
69Engineers Gate Manager LP36,531New0.06%$0 MNov 16, 2026
70Marex Group Ltd35,2500 (0.00%)0.06%$0 MNov 16, 2026
71Aigen Investment Management, LP33,858New0.06%$0 MNov 16, 2026
72Jpmorgan Chase & Co29,803+7,195 (+31.83%)0.05%$0 MNov 12, 2026
73Russell Investments Group, Ltd.27,847-622 (-2.18%)0.05%$0 MNov 6, 2026
74MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.25,379+1,284 (+5.33%)0.04%$0 MNov 16, 2026
75Invesco Ltd.24,943-1,913 (-7.12%)0.04%$0 MNov 12, 2026
76MetLife Investment Management, LLC21,153-7,225 (-25.46%)0.03%$0 MNov 16, 2026
77Barclays PLC20,845+2,238 (+12.03%)0.03%$0 MNov 6, 2026
78Vanguard Global Advisers, LLC20,371+244 (+1.21%)0.03%$0 MNov 13, 2026
79Centiva Capital, LP19,318New0.03%$0 MNov 13, 2026
80LPL Financial LLC19,050-80 (-0.42%)0.03%$0 MNov 6, 2026
81Alliancebernstein L.P.18,0400 (0.00%)0.03%$0 MNov 16, 2026
82Police & Firemen's Retirement System of New Jersey17,5690 (0.00%)0.03%$0 MNov 9, 2026
83Tower Research Capital LLC (TRC)17,306+12,316 (+246.81%)0.03%$0 MNov 16, 2026
84Prelude Capital Management, LLC17,050-2,563 (-13.07%)0.03%$0 MNov 16, 2026
85Manufacturers Life Insurance Company, The15,854+976 (+6.56%)0.03%$0 MNov 13, 2026
86Susquehanna International Group, LLP15,614-24,766 (-61.33%)0.03%$0 MNov 16, 2026
87BNP Paribas Financial Markets12,668+5,132 (+68.10%)0.02%$0 MNov 12, 2026
88Jain Global LLC12,300-8,700 (-41.43%)0.02%$0 MNov 16, 2026
89Voya Investment Management LLC11,4690 (0.00%)0.02%$0 MNov 10, 2026
90Wells Fargo & Company/mn11,160-43,436 (-79.56%)0.02%$0 MNov 16, 2026
91Commonwealth Equity Services, LLC11,0000 (0.00%)0.02%$0 MNov 2, 2026
92Essential Partners LLC10,842+1,040 (+10.61%)0.02%$0 MOct 14, 2026
93Brevan Howard Capital Management LP10,025New0.02%$0 MNov 16, 2026
94Simplex Trading, LLC8,450+8,111 (+2392.63%)0.01%$0 MNov 4, 2026
95New York State Common Retirement Fund7,9000 (0.00%)0.01%$0 MNov 17, 2026
96Royal Bank Of Canada6,294-1,469 (-18.92%)0.01%$0 MNov 16, 2026
97Larson Financial Group LLC6,105New0.01%$0 MNov 5, 2026
98Northwestern Mutual Wealth Management Co6,000New0.01%$0 MNov 13, 2026
99Legal & General Group Plc4,4900 (0.00%)0.01%$0 MNov 16, 2026
100Ameritas Investment Partners, Inc.3,2980 (0.00%)0.01%$0 MNov 13, 2026

All 119 institutional investors, with who bought and sold →

Mutual funds holding Protara Therapeutics, Inc.#

97 funds hold shares worth $34 M (about 13.8% of the company). Since their previous reports 55 added shares and 8 sold, buying $8 M net.
Mutual funds holding Protara Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.66 M$6 M2.7%<0.01%+7.5%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.36 M$5 M2.2%<0.01%+12%Jun 30, 2026
🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC758,070$3 M1.2%0.12%newJul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.586,965$2 M0.95%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC569,271$2 M0.92%<0.01%+12%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors475,364$2 M0.77%0.01%+9.1%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.264,329$1 M0.43%<0.01%+51%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC241,686$1 M0.39%<0.01%+32%May 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP182,472$1 M0.30%<0.01%+23%Jul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors175,831$1 M0.29%0.04%+36%Jun 30, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.141,979$1 M0.23%0.04%+20%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP131,860$1 M0.21%<0.01%+82%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP125,321$0 M0.20%<0.01%−30%Jul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.122,956$0 M0.20%<0.01%+8.9%Jul 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.117,674$0 M0.19%0.07%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust91,844$0 M0.15%0.02%+13%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC83,341$0 M0.14%<0.01%+42%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC68,889$0 M0.11%<0.01%+41%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC83,507$0 M0.14%<0.01%no changeJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC78,000$0 M0.13%0.20%+24%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC73,022$0 M0.12%0.01%+14%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC70,086$0 M0.11%<0.01%+14%Jul 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.55,748$0 M0.09%0.16%+21%May 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC65,107$0 M0.11%0.04%+24%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC51,733$0 M0.08%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.39,575$0 M0.06%0.01%+54%May 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC44,729$0 M0.07%<0.01%+1672%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC31,457$0 M0.05%<0.01%+13%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.35,000$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I27,260$0 M0.04%<0.01%newMay 31, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS30,200$0 M0.05%0.03%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.28,387$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.26,902$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC26,054$0 M0.04%<0.01%+9.6%Jul 31, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS26,300$0 M0.04%0.05%newJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company21,256$0 M0.03%<0.01%+59%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation25,700$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC24,988$0 M0.04%<0.01%+12%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.25,444$0 M0.04%<0.01%−2.6%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC22,692$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP21,419$0 M0.03%<0.01%+38%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.21,779$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP20,174$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC19,600$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC19,061$0 M0.03%<0.01%+19%Jul 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP18,477$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.17,400$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC16,303$0 M0.03%<0.01%−2.4%Jun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP14,686$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC10,978$0 M0.02%0.03%—Mar 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC13,318$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP11,973$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC11,866$0 M0.02%0.02%+30%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC11,635$0 M0.02%<0.01%+23%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC10,298$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC10,434$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS10,057$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC9,020$0 M0.01%<0.01%+259%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC9,020$0 M0.01%<0.01%+259%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.8,393$0 M0.01%<0.01%+17%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC8,362$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC8,096$0 M0.01%<0.01%+17%Jul 31, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP7,914$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.7,890$0 M0.01%<0.01%+38%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC7,712$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC7,440$0 M0.01%<0.01%+38%Jun 30, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP7,228$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP6,250$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC6,128$0 M<0.01%<0.01%+68%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC6,087$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,824$0 M<0.01%<0.01%+3.8%Jul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP5,791$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP4,825$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC4,279$0 M<0.01%<0.01%+140%Jul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS4,120$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,184$0 M<0.01%<0.01%+56%Jun 30, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC3,365$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,029$0 M<0.01%<0.01%+25%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust3,240$0 M<0.01%0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,185$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP3,715$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC3,764$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,333$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,298$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC2,994$0 M<0.01%<0.01%+24%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION2,400$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,419$0 M<0.01%<0.01%+58%May 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,607$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,912$0 M<0.01%<0.01%−12%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,891$0 M<0.01%<0.01%−13%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,196$0 M<0.01%<0.01%−33%Jun 30, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC1,836$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,714$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,133$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,107$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC991$0 M<0.01%<0.01%+32%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC792$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 97 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Protara Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$1.0 M
3 sales, 2 insiders
Net, 12 months
-$1.0 M
open market only
Insiders on file
37
since
$64 K-$971 K$0May 2024: bought $0 (0 trades), sold $971 K (12 trades)May 24Jun 2024: bought $0 (0 trades), sold $171 K (6 trades)JunJul 2024: bought $0 (0 trades), sold $221 K (10 trades)JulSep 2024: bought $0 (0 trades), sold $386 K (8 trades)SepMar 2025: bought $0 (0 trades), sold $96 K (1 trades)MarMay 2025: bought $64 K (1 trades), sold $0 (0 trades)MayApr 2026: bought $0 (0 trades), sold $125 K (2 trades)AprJun 2026: bought $0 (0 trades), sold $882 K (1 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Protara Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jesse SheffermanCEO and President, DirectorGift-14,000——707,832Form 4
filed Jesse SheffermanCEO and President, DirectorGift-7,000——700,832Form 4
filed Jesse SheffermanCEO and President, DirectorGift-4,000——696,832Form 4
filed Jesse SheffermanCEO and President, DirectorGift-5,000——691,832Form 4
filed Jesse SheffermanCEO and President, DirectorOption exercise+215,687$1.910$412 K937,519Form 4
filed Jesse SheffermanCEO and President, DirectorSell-215,687$4.090$882 K721,832Form 4
filed William ConklingChief Commercial OfficerShares withheld for tax-6,008$4.340$26 K69,992Form 4
filed Jacqueline ZummoChief R&D OfficerSell10b5-1 plan-1,134$5.400$6 K94,827Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Protara Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.2 M
6.0% of shares · 2.87 days to cover
Buybacks, Q1 2024
$0.1M
Q1 2024
Shares sold short, last 24 reportsAll stocks →
Protara Therapeutics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2024Q1 2024$0.1M
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$0.1M
Q4 2022Q4 2022$0M
Q3 2022Q3 2022$0M
Q2 2022Q2 2022$0M
Q1 2022Q1 2022$0.1M
Q4 2021Q4 2021$0M
Q3 2021Q3 2021$0M
Q2 2021Q2 2021$0M
Q1 2021Q1 2021$0.2M

Trading halts

  • 2024-12-05 14:44 UTC, code LUDP, resumed 14:54 UTC

Fails to deliver

  • : 21 shares at $3.82
  • : 1,248 shares at $3.97
  • : 104 shares at $3.94
  • : 5 shares at $3.81
  • : 675 shares at $3.90

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Protara Therapeutics, Inc. scorecard#

Passes 1 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.34 vs -2.17Diluted EPS -1.34 in fiscal 2025 against -2.17 the year before (report's currency).
    • ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$34 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-31.6%-31.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.58 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year108.0%Diluted shares up 108.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Protara Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Protara Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development4332251721123.9r122219
General and administrative2217192126224.0r9.58.79.8
Operating expenses6549446747347.8r213029
Operating income−65−49−44−67−47−34−7.8r−21−30−29
Interest and finance income6.44.23.21.10.20.5————
Interest expense and finance costs————00.0————
Net interest income—————−0.0r————
Other non-operating income (expense)7.14.63.21.10.20.50.30.60.40.2
Income before tax5745————−15−21−30−29
Net income including minority interests————−47−34−7.8———
Net income attributable to shareholders−57−45−40−66−47−34−7.8r−21−30−29
Earnings per share, basic-1.34-2.17-3.57-5.86-4.21-4.70-3.04r-45.80r-2.13-1.72
Earnings per share, diluted-1.34-2.17-3.57-5.86-4.21-4.70-3.04r-45.80r-2.13-1.72
Shares, weighted average (basic)43211111——————
Shares, weighted average (diluted)43211111117.22.6r0.5r1717
Balance sheet
Cash and cash equivalents501634024361690.6r192136
Short-term investments1067.5266056—————
Other current assets0.10.00.00.10.00.1r0.1r1.41.31.4
Current assets1601726986931690.8r234343
Property, plant and equipment0.81.01.31.61.71.20.5r0.30.30.4
Right-of-use (leased) assets3.24.35.36.37.21.1————
Goodwill————3030————
Total assets209181791131732031.2r244444
Accounts payable3.54.42.41.61.00.90.7r0.40.30.6
Debt due within a year————00————
Current liabilities11116.15.74.32.93.4r3.19.25.1
Lease liabilities (non-current)2.13.44.55.56.41.0————
Total liabilities13141111113.93.4r3.19.25.1
Retained earnings−302−245−200−160−94−47−13r−210−190−160
Shareholders' equity19616768102162199−2.1r4.8r35r38
Total liabilities and equity209181791131732031.2r244444
Shares outstanding5435111111112.6r0.5r1817
Cash-flow statement
Depreciation and amortization—————————0.1
Share-based compensation3.84.16.16.7109.70.4r3.43.23.3
Cash from operating activities−56−36−38−26−35−23−5.0r−23−22−24
Capital expenditure−0.1−0.1−0.0−0.1−0.6−0.9−0.5r−0.1−0.0−0.3
Acquisitions, net of cash acquired—————−3.7————
Cash from investing activities−139195315−982.8−0.5r18−1620
Shares issued—————74r————
Shares bought back——−0.1−0.1−0.2—————
Cash from financing activities83140−0.1−0.1−0.21890.53.0230.2
Exchange-rate effect on cash————————0.2−0.1
Change in cash——————−13−1.8−15−3.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Protara Therapeutics, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 5 subsidiaries on file.

Protara Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office3 subsidiaries—
🇧🇲 Bermuda1 subsidiary—
🇮🇪 Ireland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Protara Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.7 M
Mr. Shefferman
Other top executives, average
$1.4 M
the CEO earned 1.9× this
$100 invested is now
$199
Protara Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Shefferman$2.7 M$2.3 M$1.4 M$199
2024Mr. Shefferman$1.8 M$4.4 M$1.1 M$197
2023Mr. Shefferman$1.9 M$1.3 M$1.2 M$70

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Protara Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 11

Protara Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Protara Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2017$22 MPrivate placement after listing$10 to $50 million11equity, optionsSEC
May 2014$30 MNo. 3$10 to $50 million22equitySEC
Sep 2013$4 MNo. 2$2 to $10 million17equity, debt, optionsSEC
Aug 2011$15 MNo. 1$10 to $50 million19equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Protara Therapeutics, Inc. compares in Biotechnology

  • Market cap$235 M · higher than 46% of 726
  • Price / book1.2× · lower than 75% of 534
  • FCF yield-24.0% · higher than 40% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Protara Therapeutics, Inc.🇺🇸$235 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Protara Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Protara Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Protara Therapeutics, Inc.? Suggest a correction